An observational study in Sudden Cardiac Death, sponsored by University of Luebeck. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-07-01.
Sponsored by University of Luebeck · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Death, Sudden, Cardiac with a site in Germany — 6 open to participants now, 7 under way, none of them phase 3. Death, Sudden, Cardiac · Germany.
Among the 43 studies in Death, Sudden, Cardiac with a site in Germany, this one is the 2nd largest by planned enrollment of the 24 observational ones that give a count, is the only one that started in 2022, is one of 24 observational ones, and was the 39th registered.
364 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.
Browse Death, Sudden, Cardiac studies →6 of the 43 studies in Death, Sudden, Cardiac with a site in Germany are open now. Recruiting first, the newest first:
Universitätsklinikum Köln · Sites in Germany
Charite University, Berlin, Germany · Sites in Germany, Austria, Belgium and 10 more countries
Ages 18+
Western Sydney Local Health District · Sites in Germany, United States, Australia and 12 more countries
Ages 18–85
Klinik für Kardiologie, Pneumologie und Angiologie · Sites in Germany
Ages 18–80
Universitätsklinikum Köln · Sites in Germany
Ages 8+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 63 Death, Sudden, Cardiac studies recruiting now, 42 (67%) set no upper age limit and 11 (17%) stop at 75 or younger; 22 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 4,000 is above the median of 450 across 203 observational studies indexed under Death, Sudden, Cardiac.
Median enrollment 180 across the 18 interventional studies, 410 across the 24 observational. Of the 27 that completed or were terminated, 4 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 43 have an industry lead sponsor. The 10 most frequent:
University of Luebeck is the lead sponsor of 76 studies on the registry; 13 are open to participants now.
University of Luebeck has 1 study filed under Death, Sudden, Cardiac — fewer than ten, so there is no comparison to draw.
1 of the studies in Death, Sudden, Cardiac with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05665608Charite University, Berlin, GermanyPrevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies in Death, Sudden, Cardiac with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The entirely subcutaneous implantable defibrillator (S-ICD) (Emblem, Boston Scientific, Marlborough, MA, USA) was introduced as a new therapeutic alternative to the conventional transvenous ICD in 2009 and implantations are rapidly expanding since then.1 Implantation of the S-ICD seems to reduce implant-related perioperative complications such as pneumothorax, hematoma and cardiac tamponade.
The aim of this multicenter registry is thus to assess the outcome of patients following an S-ICD implantation in a real-world setting.
The S-ICD has a CE mark and is FDA approved since 2012 and is mentioned as a potential therapy strategy in the current AHA guidelines on the management of patients with ventricular arrhythmias.2 However, although implant-related complications seem to be reduced by the S-ICD in randomized controlled trials, the rate of inappropriate shocks remains high in S-ICD patients (10-13%).3-5 The most common reason for inappropriate shocks is cardiac oversensing, mostly due to T-wave oversensing or low amplitude of the subcutaneous signal, which not commonly found in patients with transvenous ICDs. Data on the role of the Defibrillation Threshold Testing (DFT), the rate of infectious complications (lead or device complications), the use of the S-ICD in children and adolescents, and the outcome of patients with an S-ICD according to their underlying cardiac substrate are sparse. The aim of this multicenter registry is thus to assess the outcome of patients following an S-ICD implantation in a real-world setting with a special focus on perioperative complication rate, the role of DFT testing in S-ICD, the use of the S-ICD in cohorts that are underrepresented in clinical studies (adolescents and geriatrics), the outcome and risk factors of ineffective, inappropriate and appropriate shocks and the differences in outcomes according to the underlying cardiac disease.
Patients in whom a S-ICD was implanted for primary or secondary prevention
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Overall complication rate
combination of device related complications and inappropriate shocks
Time frame: through study completion, an average of 2 years
Rate of appropriate shocks
Appropriate therapies delivered by the devices
Time frame: through study completion, an average of 2 years
Rate of inappropriate shocks
Inappropriate therapies delivered by the devices
Time frame: through study completion, an average of 2 years
Device-related complication rate
Rate of complications pertaining to the device
Time frame: immediately after the intervention/procedure/surgery"
DFT impact
Impact of defibrillator function test (DFT) on long term arrhythmia outcome or mortality
Time frame: 2 year
Rate of replacements
Generator replacements
Time frame: 2 year
Role of Gender in primary outcomes
Analysis of the potential role of gender on the primary outcomes
Time frame: through study completion, an average of 2 year
Rate of device upgrades
need for device upgrade due to pacing needs
Time frame: through study completion, an average of 2 year
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2022 (actual). Primary completion is estimated for Jun 2025, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Luebeck